Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana

Authors: Adam VanDeusen, Elijah Paintsil, Thomas Agyarko-Poku, Elisa F Long

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

Achieving the goal of eliminating mother-to-child HIV transmission (MTCT) necessitates increased access to antiretroviral therapy (ART) for HIV-infected pregnant women. Option B provides ART through pregnancy and breastfeeding, whereas Option B+ recommends continuous ART regardless of CD4 count, thus potentially reducing MTCT during future pregnancies. Our objective was to compare maternal and pediatric health outcomes and cost-effectiveness of Option B+ versus Option B in Ghana.

Methods

A decision-analytic model was developed to simulate HIV progression in mothers and transmission (in utero, during birth, or through breastfeeding) to current and all future children. Clinical parameters, including antenatal care access and fertility rates, were estimated from a retrospective review of 817 medical records at two hospitals in Ghana. Additional parameters were obtained from published literature. Modeled outcomes include HIV infections averted among newborn children, quality-adjusted life-years (QALYs), and cost-effectiveness ratios.

Results

HIV-infected women in Ghana have a lifetime average of 2.3 children (SD 1.3). Projected maternal life expectancy under Option B+ is 16.1 years, versus 16.0 years with Option B, yielding a gain of 0.1 maternal QALYs and 3.2 additional QALYs per child. Despite higher initial ART costs, Option B+ costs $785/QALY gained, a value considered very cost-effective by World Health Organization benchmarks. Widespread implementation of Option B+ in Ghana could theoretically prevent up to 668 HIV infections among children annually. Cost-effectiveness estimates remained favorable over robust sensitivity analyses.

Conclusions

Although more expensive than Option B, Option B+ substantially reduces MTCT in future pregnancies, increases both maternal and pediatric QALYs, and is a cost-effective use of limited resources in Ghana.
Appendix
Available only for authorised users
Literature
4.
go back to reference Baiden F, Baiden R, Williams J, Akweongo P, Clerk C, Debpuur C, et al. Review of antenatal-linked voluntary counseling and HIV testing in Sub-Saharan Africa: lessons and options for Ghana. Ghana Me J. 2005;39:8–13. Baiden F, Baiden R, Williams J, Akweongo P, Clerk C, Debpuur C, et al. Review of antenatal-linked voluntary counseling and HIV testing in Sub-Saharan Africa: lessons and options for Ghana. Ghana Me J. 2005;39:8–13.
8.
go back to reference Shah M, Johns B, Abimiku A, Walker DG. Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. AIDS. 2011;25:1093–102.CrossRefPubMed Shah M, Johns B, Abimiku A, Walker DG. Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. AIDS. 2011;25:1093–102.CrossRefPubMed
9.
go back to reference Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A, et al. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis. 2013;56:430–46.CrossRefPubMed Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A, et al. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis. 2013;56:430–46.CrossRefPubMed
10.
go back to reference Kuznik A, Lamorde M, Hermans S, Castelnuovo B, Auerbach B, Semeere A, et al. Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda. Bull World Health Organ. 2012;90:595–603.CrossRefPubMedPubMedCentral Kuznik A, Lamorde M, Hermans S, Castelnuovo B, Auerbach B, Semeere A, et al. Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda. Bull World Health Organ. 2012;90:595–603.CrossRefPubMedPubMedCentral
11.
go back to reference Fasawe O, Avila C, Shaffer N, Schouten E, Chimbwandira F, Hoos D, et al. Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. PLoS One. 2013;8:e57778.CrossRefPubMedPubMedCentral Fasawe O, Avila C, Shaffer N, Schouten E, Chimbwandira F, Hoos D, et al. Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. PLoS One. 2013;8:e57778.CrossRefPubMedPubMedCentral
12.
go back to reference National AID, Program C. PMTCT training package for health care providers participant manual. Accra: Ghana Health Service; 2010. National AID, Program C. PMTCT training package for health care providers participant manual. Accra: Ghana Health Service; 2010.
13.
go back to reference When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–63.CrossRefPubMedCentral When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–63.CrossRefPubMedCentral
14.
go back to reference Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA. 2001;285:1466–74.CrossRefPubMed Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA. 2001;285:1466–74.CrossRefPubMed
15.
go back to reference Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. JAIDS. 2006;42:464–9.PubMed Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. JAIDS. 2006;42:464–9.PubMed
16.
go back to reference Deeks SG, Grant RM. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir Ther. 1999;4 Suppl 3:7–11.PubMed Deeks SG, Grant RM. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir Ther. 1999;4 Suppl 3:7–11.PubMed
19.
go back to reference Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22:475–81.CrossRefPubMed Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22:475–81.CrossRefPubMed
23.
go back to reference Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–8.CrossRefPubMed Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–8.CrossRefPubMed
27.
go back to reference van Hulst M, Sagoe KW, Vermande JE, van der Schaaf IP, van der Tuuk Adriani WP, Torpey K, et al. Cost-effectiveness of HIV screening of blood donations in Accra (Ghana). Value Health. 2008;11:809–19.CrossRefPubMed van Hulst M, Sagoe KW, Vermande JE, van der Schaaf IP, van der Tuuk Adriani WP, Torpey K, et al. Cost-effectiveness of HIV screening of blood donations in Accra (Ghana). Value Health. 2008;11:809–19.CrossRefPubMed
28.
29.
go back to reference Long E, Stavert RR. Portfolios of biomedical HIV interventions in south Africa: a cost-effectiveness analysis. J Gen Intern Med. 2013;28(10):1294–301.CrossRefPubMedPubMedCentral Long E, Stavert RR. Portfolios of biomedical HIV interventions in south Africa: a cost-effectiveness analysis. J Gen Intern Med. 2013;28(10):1294–301.CrossRefPubMedPubMedCentral
30.
go back to reference Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005;331:1431–7.CrossRefPubMedPubMedCentral Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005;331:1431–7.CrossRefPubMedPubMedCentral
31.
go back to reference Achana FS, Debpuur C, Akweongo P, Cleland J. Postpartum abstinence and risk of HIV among young mothers in the Kassena-Nankana District of Northern Ghana. Cult Health Sex. 2010;12:569–81.CrossRefPubMed Achana FS, Debpuur C, Akweongo P, Cleland J. Postpartum abstinence and risk of HIV among young mothers in the Kassena-Nankana District of Northern Ghana. Cult Health Sex. 2010;12:569–81.CrossRefPubMed
Metadata
Title
Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana
Authors
Adam VanDeusen
Elijah Paintsil
Thomas Agyarko-Poku
Elisa F Long
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-0859-2

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.